| Description | Amitifadine(DOV-21947, EB-1010) is an inhibitor of the so-called triple reuptake or serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) and is an antidepressant drug candidate. Amitifadine reduces binge drinking and negative affect in an animal model of co-occurring alcoholism and depression symptomatology. |
| Synonyms | DOV 21947, DOV-21947, DOV21,947, DOV21947, DOV 21,947, DOV-21,947 |
| molecular weight | 228.12 |
| Molecular formula | C11H11Cl2N |
| CAS | 410074-73-6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Levin ED, Wells C, Johnson JE, Rezvani AH, Bymaster FP, Rose JE. Amitifadine, a triple monoamine re-uptake inhibitor, reduces nicotine self-administration in female rats. Eur J Pharmacol. 2015 Oct 5;764:30-7. doi: 10.1016/j.ejphar.2015.06.041. Epub 2015 Jun 20. PubMed PMID: 26101069. 2. Miller LL, Leitl MD, Banks ML, Blough BE, Negus SS. Effects of the triple monoamine uptake inhibitor amitifadine on pain-related depression of behavior and mesolimbic dopamine release in rats. Pain. 2015 Jan;156(1):175-84. doi: 10.1016/j.pain.0000000000000018. PubMed PMID: 25599313; PubMed Central PMCID: PMC4351716. 3. Bymaster FP, Chao P, Schulze H, Tran PV, Marshall RD. Biopharmaceutical characterization, metabolism, and brain penetration of the triple reuptake inhibitor amitifadine. Drug Metab Lett. 2013 Mar;7(1):23-33. PubMed PMID: 23826879. 4. Warnock KT, Yang AR, Yi HS, June HL Jr, Kelly T, Basile AS, Skolnick P, June HL. Amitifadine, a triple monoamine uptake inhibitor, reduces binge drinking and negative affect in an animal model of co-occurring alcoholism and depression symptomatology. Pharmacol Biochem Behav. 2012 Nov;103(1):111-8. PubMed PMID: 22884707; PubMed Central PMCID: PMC3537915. |